OBJECTIVE To assess the costs of the Smoking Cessation Program in the Brazilian Unified Health System and estimate the cost of its full implementation in a Brazilian municipality.METHODS The intensive behavioral therapy and treatment for smoking cessation includes consultations, cognitive-behavioral group therapy sessions, and use of medicines. The costs of care and management of the program were estimated using micro-costing methods. The full implementation of the program in the municipality of Goiania, Goias was set as its expansion to meet the demand of all smokers motivated to quit in the municipality that would seek care at Brazilian Unified Health System. We considered direct medical and non-medical costs: human resources, medicines, consumables, general expenses, transport, travels, events, and capital costs. We included costs of federal, state, and municipal levels. The perspective of the analysis was that from the Brazilian Unified Health System. Sensitivity analysis was performed by varying parameters concerning the amount of activities and resources used. Data sources included a sample of primary care health units, municipal and state secretariats of health, and the Brazilian Ministry of Health. The costs were estimated in Brazilian Real (R$) for the year of 2010.RESULTS The cost of the program in Goiania was R$429,079, with 78.0% regarding behavioral therapy and treatment of smoking. The cost per patient was R$534, and, per quitter, R$1,435. The full implementation of the program in the municipality of Goiania would generate a cost of R$20.28 million to attend 35,323 smokers.CONCLUSIONS The Smoking Cessation Program has good performance in terms of cost per patient that quit smoking. In view of the burden of smoking in Brazil, the treatment for smoking cessation must be considered as a priority in allocating health resources.

Objectives: Little information exists on the acute treatment provided for rhinosinusitis and its associated costs. We hypothesize that introducing the administration of mometasone furoate (MFNS) as a treatment for rhinosinusitis will have a substantial impact on medical resource costs, outcomes and possibly cost-effectiveness. The goal of this paper is to estimate the cost-effectiveness of treating patients with rhinosinusitis with MFNS versus amoxicillin. MethOds: A decision-analytic model was developed to estimate lifetime costs and outcomes associated with MFNS 200µg twice daily and amoxicillin 500mg three times daily in treating rhinosinusitis from the Mexican health care perspective. This study further do not included MFNS 200µg once daily as a treatment arm because it was not found to be superior to amoxicillin. Data sources included published literature, clinical trials, official price/tariff lists, and Delphi panel data. The time horizon was 2 weeks. The effectiveness outcomes of the study were modeled as changes in the Major Symptom Score (MSS). MSS consists of five questions concerning rhinorrhoea, post-nasal drip, nasal congestion, sinus headache, and facial pain. Costs were valued in US dollar, year 2012 values. Multiple 1-way sensitivity analyses and a probabilistic sensitivity analysis using Monte Carlo simulation were performed to handle uncertainty. Results: The projected costs were US$ 258 with MFNS and $US 272 with. The benefits (changes in the MSS) were 0.52 with MFNS 0.45 with Amoxicilin. MFNS was associated with a cost savings per patient of US$ 14 versus amoxicillin over a period of 2 weeks from a health care perspective. The incremental cost-effectiveness ratio for MFNS dominated Amoxicilin. Sensitivity analysis confirmed the overall cost savings and gains in effectiveness. cOnclusiOns: Our analysis suggests MFNS improves health outcomes in a cost-effective manner compared with Amoxicilin. The economic value of Amoxicillin is influenced by difficulties involved in diagnosing the condition, effectiveness, resistance, patient compliance with treatment, and treatment failure associated with antibiotics. RespiRatoRy-Related disoRdeRs -Health Care Use & policy studies pRs12 tHe impaCt of pUbliC foRmUlaRies & GUidelines on CommUnity aCqUiRed pneUmonia (Cap) dRUGs in mexiCo